Systematic review of antiplatelet therapy for the prevention of myocardial infarction, stroke or vascular death in patients with peripheral vascular disease

Abstract

Antiplatelet therapy reduces serious vascular events and vascular death in patients with PVD. For infrainguinal arterial surgery or balloon angioplasty the benefit remains unproven, but the number of trials to date is small. There is also evidence to support the use of antiplatelet drugs other than aspirin for the prevention of vascular events in those with PVD.

Preparation and characterization of acetylsalicylic acid/chitosan nanoparticles and its antithrombotic effects

“…Acetylsalicylic acid (ASA) had significant anti-platelet aggregation function [1] and it had been used for the prevention and treatment of AMI and thrombosis diseases from 1970s [2]. Evidence-based studies had proved that ASA could reduce the incidence rate of 25% of heart and brain and peripheral thromboembolic disease [3,4]. Especially for myocardial infarction and stroke, long-term use of the low-dose acetylsalicylic acid (ASA) could significantly reduce the incidence of this diseases.…”

Efficacy and Safety of Aspirin in Patients With Peripheral Vascular Disease: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials

“…However, benefit in patients with established atherosclerosis without evidence of an ischemic event has recently been questioned [6]. Prior meta-analyses have yielded inconsistent findings with regard to the benefit of aspirin in PVD [7][8][9]. One reason for the disparate results of these meta-analyses is the heterogeneity of patients enrolled in the studies as well as the inclusion of studies with other antiplatelet agents, such as cilostazol or clopidogrel, as comparators.…”

Prevention, epidemiology, and prognosis of perioperative ­myocardial injury

“…RCTs showed mixed results but with a potential decreased risk of vascular events in patients on ASA in the perioperative period [46][47][48]. In contrast, the PEP trial, involving 13 356 patients undergoing hip surgery, demonstrated more cardiac ischaemic events (death due to ischaemic heart disease or nonfatal MI) in patients randomised to ASA versus placebo (HR 1.33, 95% CI 1.00-1.78) [49].…”